{"schema_version":"1","generated_at":"2026-10-28T17:28:34.176Z","data_as_of":null,"url":"https://www.findmykol.com/kol/godson-oguchi","json_url":"https://www.findmykol.com/kol/godson-oguchi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"godson-oguchi","name":"Godson Oguchi","credential":"MD","specialty":"Infectious Disease","specialty_raw":"Infectious Disease","therapeutic_area":"Infectious Disease","therapeutic_areas":["Infectious Disease"],"city":"Orange City","state":"FL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1245200906","openalex":"A5070773342"},"summary":"Godson Oguchi is an Infectious Disease physician. OpenAlex indexes 17 publications with 2,590 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Infectious Disease"]},"scholarship":{"works_count":17,"cited_by_count":2590,"h_index":8,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":25,"program_years":{"first":2021,"last":null},"rows_total":66,"shown":3,"withheld":63,"rows":[{"payer":"ViiV Healthcare Company","program_year":2025,"amount_usd":600.88,"payment_count":27,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245200906"},{"payer":"Gilead Sciences, Inc.","program_year":2025,"amount_usd":391.66,"payment_count":14,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245200906"},{"payer":"Merck Sharp & Dohme LLC","program_year":2025,"amount_usd":218.18,"payment_count":9,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245200906"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1245200906","source":"payments"},"publications":{"total":19,"shown":5,"withheld":14,"matched_by":"OpenAlex author record","recent":[{"title":"Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI","year":2024,"journal":"Infectious Diseases and Therapy","source_url":"https://doi.org/10.1007/s40121-024-01007-z","status":"verified"},{"title":"Activité antivirale, tolérance et pharmacocinétique du GS-1720, un nouvel INI oral hebdomadaire","year":2024,"journal":"Médecine et Maladies Infectieuses Formation","source_url":"https://doi.org/10.1016/j.mmifmc.2024.04.383","status":"verified"},{"title":"Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI","year":2024,"journal":"Infectious Diseases and Therapy","source_url":"https://doi.org/10.1007/s40121-024-01036-8","status":"verified"},{"title":"Erratum à Activité antivirale, tolérance et pharmacocinétique du GS-1720, un nouvel INI oral hebdomadaire [Médecine et Maladies Infectieuses Formation (2024) S139]","year":2024,"journal":"Médecine et Maladies Infectieuses Formation","source_url":"https://doi.org/10.1016/j.mmifmc.2024.06.008","status":"verified"},{"title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","year":2023,"journal":"The Lancet Diabetes & Endocrinology","source_url":"https://doi.org/10.1016/s2213-8587(23)00322-4","status":"verified"}],"source":"works"},"contact":{"address_1":"955 TOWN CENTER DR","address_2":"SUITE 100","city":"Orange City","state":"FL","zip":"327638255","phone":"386-228-0661","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1245200906","source":"identity"},"similar":[{"name":"Thomas Walsh","slug":"thomas-walsh","institution":"Cornell University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/thomas-walsh","json_url":"https://www.findmykol.com/kol/thomas-walsh/profile.json"},{"name":"Douglas Richman","slug":"douglas-richman","institution":"University of California San Diego","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/douglas-richman","json_url":"https://www.findmykol.com/kol/douglas-richman/profile.json"},{"name":"Vance Fowler","slug":"vance-fowler","institution":"Duke University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/vance-fowler","json_url":"https://www.findmykol.com/kol/vance-fowler/profile.json"},{"name":"Myron Cohen","slug":"myron-cohen","institution":"University of North Carolina at Chapel Hill School of Medicine","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/myron-cohen","json_url":"https://www.findmykol.com/kol/myron-cohen/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":63,"publications":14}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2021-01-28","provider_certified":"2021-01-28","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}